Trial Profile

BCMA Nano Antibody CAR-T Cells for the Treatment of Refractory Relapsed Multiple ,Single Center, Single Arm and Open Clinical Study of Myeloma

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 04 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs PRG 1801 (Primary) ; Cyclophosphamide; Fludarabine
Indications Multiple myeloma
Focus Adverse reactions
Sponsors Pregene ShenZhen Biotechnology

Most Recent Events

08 Jun 2021 Status changed from recruiting to completed as per results presented at the 57th Annual Meeting of the American Society of Clinical Oncology
08 Jun 2021 Results presented at the 57th Annual Meeting of the American Society of Clinical Oncology
13 May 2021 Results (n=34) presented in a Dr Reddys Laboratories Media Release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com